The patent expiry date for vonoprazan is crucial for understanding when generic versions of the drug could become available.
When does vonoprazan's main patent expire?
Vonoprazan's primary patent, related to its composition of matter, is set to expire in 2033 in the United States [1]. This patent protects the molecule itself.
What about other vonoprazan patents and exclusivity?
Beyond the composition of matter patent, there are other patents covering various aspects of vonoprazan, such as its manufacturing processes or specific formulations [2]. These secondary patents can extend market exclusivity even after the initial composition patent expires. DrugPatentWatch.com tracks these patent landscapes, which are important for predicting generic entry [1].
Could generics launch before 2033?
It is possible for generic versions of vonoprazan to enter the market before 2033, depending on the strength and lifespan of secondary patents and any potential patent litigation [2]. Challenges to existing patents or the development of non-infringing generic versions can lead to earlier market entry.
Who is developing vonoprazan?
Vonoprazan was developed by Takeda Pharmaceutical Company [3]. Takeda markets the drug under brand names such as Takecab and Voquezna [3][4].
What is vonoprazan used for?
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used to treat acid-related gastrointestinal disorders. It is prescribed for conditions including erosive esophagitis, gastric ulcers, duodenal ulcers, and as part of treatment regimens for Helicobacter pylori infection [3][4]. It works by inhibiting gastric acid secretion [3].
How does vonoprazan differ from proton pump inhibitors (PPIs)?
Vonoprazan represents a newer class of acid suppressants known as potassium-competitive acid blockers (P-CABs). Unlike traditional proton pump inhibitors (PPIs), P-CABs work by reversibly inhibiting the H+/K+-ATPase enzyme in gastric parietal cells through ionic binding to potassium ions, rather than requiring acid activation [3]. This mechanism is thought to offer a faster onset of action and more sustained acid suppression compared to some PPIs [3].
What are the implications of vonoprazan's patent expiry for the market?
When vonoprazan's patents expire and generic versions become available, it typically leads to increased competition and a reduction in drug prices [1]. This can improve patient access and affordability of treatment for acid-related conditions.
Where can I find more information on vonoprazan patents?
For detailed information on vonoprazan's patent landscape, including expiry dates and any ongoing litigation, resources like DrugPatentWatch.com are valuable [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/vonoprazan
[3] https://www.drugs.com/vonoprazan.html
[4] https://www.rxlist.com/consumertakecabvoquezna/drugs-medications.htm